Abstract
Tacrolimus (FK506) is a new macrolide immunosuppressant isolated from Streptomyces tsukubaenesis that acts by a variety of different mechanisms, including inhibition of calcineurin. Although the mechanism of action of tacrolimus is similar to that of ciclosporin A, tacrolimus is 10 to 100 times more potent. Tacrolimus also has an effect on glucocorticoid receptor-mediated gene expression. The therapeutic efficacy of tacrolimus in primary immunosuppression has been evaluated in numerous clinical trials in patients receiving hepatic, renal, heart, lung, pancreas, intestinal, or bone marrow transplantation. Because tacrolimus displays a variety of different mechanisms of action and shows a synergism with corticosteroids, it is presumed that tacrolimus provides a new and useful therapeutic approach for autoimmune diseases, including myasthenia gravis.
Keywords: Anti-cholinesterase inhibitors, corticosteroids, immunosuppressant, FK-506 binding proteins (FKBP)-12, CYP enzyme
Current Drug Therapy
Title: Tacrolimus Treatment in Myasthenia Gravis
Volume: 2 Issue: 1
Author(s): Naoki Kawaguchi
Affiliation:
Keywords: Anti-cholinesterase inhibitors, corticosteroids, immunosuppressant, FK-506 binding proteins (FKBP)-12, CYP enzyme
Abstract: Tacrolimus (FK506) is a new macrolide immunosuppressant isolated from Streptomyces tsukubaenesis that acts by a variety of different mechanisms, including inhibition of calcineurin. Although the mechanism of action of tacrolimus is similar to that of ciclosporin A, tacrolimus is 10 to 100 times more potent. Tacrolimus also has an effect on glucocorticoid receptor-mediated gene expression. The therapeutic efficacy of tacrolimus in primary immunosuppression has been evaluated in numerous clinical trials in patients receiving hepatic, renal, heart, lung, pancreas, intestinal, or bone marrow transplantation. Because tacrolimus displays a variety of different mechanisms of action and shows a synergism with corticosteroids, it is presumed that tacrolimus provides a new and useful therapeutic approach for autoimmune diseases, including myasthenia gravis.
Export Options
About this article
Cite this article as:
Kawaguchi Naoki, Tacrolimus Treatment in Myasthenia Gravis, Current Drug Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488507779422437
DOI https://dx.doi.org/10.2174/157488507779422437 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA) – Animal Models as a Proof of Concept
Current Medicinal Chemistry Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Chlorogenic Acid Suppresses a Cell Adhesion Molecule in Experimental Autoimmune Myocarditis in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) New Insights on the Possible Role of Mast Cells in Aspirin-Induced Asthma
Current Molecular Pharmacology CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine Cellular and Molecular Mechanisms Involved in the Action of Vitamin D Analogs Targeting Vitiligo Depigmentation
Current Drug Targets Microchimerism in Health and Disease
Current Molecular Medicine The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Parasites in Rheumatoid Arthritis: Imminent Threat or Protective Effect?
Current Rheumatology Reviews Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design Autoimmune Diseases and Infections: A Controversial Relationship
Current Immunology Reviews (Discontinued) Mesenchymal Stem Cells Induced In Vitro Generated Regulatory-T Cells: Potential Soldiers of Transplantation Biology
Current Biotechnology Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics Systemic Sclerosis-Related Interstitial Lung Disease
Current Respiratory Medicine Reviews Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry